Brooklyn ImmunoTherapeutics (BTX) Competitors

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

$2.15

-0.01 (-0.46%)

(As of 04/17/2024 ET)

Stock Analysis Chart Competitors Headlines Social Media

BTX vs. CIDM, ALFIW, and NLOK

Should you be buying Brooklyn ImmunoTherapeutics stock or one of its competitors? The main competitors of Brooklyn ImmunoTherapeutics include Cinedigm (CIDM), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.

Brooklyn ImmunoTherapeutics vs.

Brooklyn ImmunoTherapeutics (NYSE:BTX) and Cinedigm (NASDAQ:CIDM) are both small-cap information companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brooklyn ImmunoTherapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Cinedigm
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Brooklyn ImmunoTherapeutics has a beta of 4.61, meaning that its stock price is 361% more volatile than the S&P 500. Comparatively, Cinedigm has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.
: In the previous week, Brooklyn ImmunoTherapeutics and Brooklyn ImmunoTherapeutics both had 1 articles in the media. Brooklyn ImmunoTherapeutics' average media sentiment score of 0.00 equaled Cinedigm'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Brooklyn ImmunoTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cinedigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Brooklyn ImmunoTherapeutics has higher earnings, but lower revenue than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Brooklyn ImmunoTherapeutics N/A N/A N/A -$2.27 -0.95
Cinedigm $72.33M 3.19 -$9.35M -$0.05 -24.70
: Company Net Margins Return on Equity Return on Assets
Brooklyn ImmunoTherapeutics N/A N/A N/A
Cinedigm N/A N/A N/A
: 26.0% of Brooklyn ImmunoTherapeutics shares are held by institutional investors. Comparatively, 8.0% of Cinedigm shares are held by institutional investors. 20.5% of Brooklyn ImmunoTherapeutics shares are held by company insiders. Comparatively, 16.4% of Cinedigm shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Brooklyn ImmunoTherapeutics and Cinedigm both received 0 outperform votes by MarketBeat users.
Company Underperform Outperform
Brooklyn ImmunoTherapeutics Outperform Votes
No Votes
Underperform Votes
68
100.00%
Cinedigm Outperform Votes
No Votes
Underperform Votes
30
100.00%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brooklyn ImmunoTherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Cinedigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brooklyn ImmunoTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cinedigm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brooklyn ImmunoTherapeutics	N/A	N/A	N/A	-$2.27	-0.95
Cinedigm	$72.33M	3.19	-$9.35M	-$0.05	-24.70

Company	Net Margins	Return on Equity	Return on Assets
Brooklyn ImmunoTherapeutics	N/A	N/A	N/A
Cinedigm	N/A	N/A	N/A

Company	Underperform	Outperform
Brooklyn ImmunoTherapeutics	Outperform Votes No Votes	Underperform Votes 68 100.00%
Cinedigm	Outperform Votes No Votes	Underperform Votes 30 100.00%

Summary

Brooklyn ImmunoTherapeutics beats Cinedigm on 4 of the 6 factors compared between the two stocks.

Ad Daily Market Alerts

Top 5 Tech Stocks to Buy for 2024

Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.

Click here to sign up for our free report & newsletter

Get Brooklyn ImmunoTherapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTX vs. The Competition

Export to Excel

Metric	Brooklyn ImmunoTherapeutics	Television Broadcasting Industry	Information Sector	NYSE Exchange
Market Cap	$126.48M	$126.48M	$3.02B	$17.17B
Dividend Yield	N/A	N/A	3.69%	3.60%
P/E Ratio	-0.95	N/A	6.83	24.59
Price / Sales	N/A	N/A	3.66	10.03
Price / Cash	N/A	N/A	N/A	16.90
Price / Book	N/A	N/A	N/A	4.85
Net Income	N/A	N/A	N/A	$965.88M
7 Day Performance	-4.87%	-4.87%	-2.78%	-3.86%
1 Month Performance	-8.51%	-8.51%	-1.92%	-2.81%
1 Year Performance	-34.85%	-34.85%	-5.78%	78.01%

Brooklyn ImmunoTherapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
CIDM Cinedigm	0 of 5 stars	$1.41 flat	N/A	N/A	$263.55M	$72.33M	-28.20	140
ALFIW Alfi	0 of 5 stars	$0.00 flat	N/A	N/A	$0.00	$200,684.00	0.00	N/A
NLOK NortonLifeLock	0 of 5 stars	$22.66 +1.8%	N/A	+15.9%	$12.95B	$2.82B	15.85	N/A

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NYSE:BTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Brooklyn ImmunoTherapeutics (BTX) Competitors

BTX vs. CIDM, ALFIW, and NLOK

Brooklyn ImmunoTherapeutics vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTX vs. The Competition

Brooklyn ImmunoTherapeutics Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info